CO₂ Inhalation and its Role in Alzheimer’s Disease: Unlocking the Glymphatic System
The medical community has long speculated that a dysfunctional glymphatic system may play a critical role in the accumulation of metabolic waste and harmful proteins in the brain, such as Beta-Amyloid and Tau. These proteins are linked to various neurodegenerative diseases, including Alzheimer’s, although they are not considered the sole causative factors.
Understanding CO₂ Inhalation and its Impact
Recent research from the University of Texas at Austin, presented by Sephira Ryman at the Alzheimer’s Association International Conference (AAIC) in London, has revealed promising results. The inhalation of elevated CO₂ concentrations may facilitate the removal of Alzheimer-associated proteins from the brain, effectively enhancing the brain’s “cleaning system.”
In their study, researchers tested twelve participants: eight showed no cognitive impairments and had normal levels of Tau proteins in their blood. In contrast, four exhibited elevated levels of a particular Tau protein variant, suggesting higher concentrations in the brain. Notably, three of these four participants suffered from mild cognitive impairments.
Activation of the Glymphatic System
During a thirty-minute experiment, participants inhaled air with either 0.05% CO₂ (similar to atmospheric levels) or 5% CO₂ at intervals of 35 seconds. Brain scans conducted alongside the experiment showed that this intermittent exposure to increased CO₂ activated the glymphatic system, which operates akin to its function during deep sleep—even as participants remained awake.
Post-experiment blood samples indicated a rise in Beta-Amyloid concentrations. This observation supports the notion that more Beta-Amyloid was effectively cleared from the brain into the bloodstream, suggesting enhanced removal capabilities.
“This indicates that this neurodegenerative marker was more effectively removed from the brain,” explains Sephira Ryman.
For participants with reduced cognitive performance, the treatment seemed to improve the clearance of Tau proteins as well. Researchers hypothesized that these individuals likely had higher concentrations of Tau proteins in their brains, which corresponded with their elevated blood levels following treatment.
Rapid Return to Baseline Levels
Additional blood samples revealed that the effects on the removal of Amyloid and Tau proteins returned to baseline levels just one hour after the treatment. This rapid regression necessitates further studies to determine whether CO₂ treatment can genuinely lower Alzheimer’s risk or positively impact disease progression.
“We just don’t know if specifically promoting clearance with such an approach will genuinely affect cognitive decline. The interesting aspect, however, is that stimulating these cleaning mechanisms is not limited to Amyloid but can assist in removing Tau, Alpha-Synuclein, and inflammatory molecules. Thus, this approach could have a broader impact on the brain and applications that extend beyond Alzheimer’s disease,” remarks Jeff Iliff.
Future Directions and Clinical Implications
Upcoming clinical studies will explore how frequently such treatments may be required and if they are deemed safe. Given that this pilot study consisted of only twelve participants with no adverse effects reported, it’s premature to draw definitive conclusions regarding safety. However, if proven safe and effective, Alzheimer’s patients and individuals at high risk could potentially utilize a small device at home to activate their brain’s cleaning systems.
In conclusion, while the preliminary results are encouraging, extensive research is warranted to fully understand the implications of CO₂ inhalation and the glymphatic system’s activation in combating neurodegenerative diseases like Alzheimer’s.
Sources
- Alzheimer’s Association International Conference (AAIC)
- Robert Klatt, July 21, 2026.
